TABLE 2.
False-negative rate of TAD for patients receiving TAD and ALND differentiating with initially cN1 and cN2/3 patients.
| Variables | Including cN2 or cN3, n/N (%) | 95% CI | Excluding cN2 or cN3, n/N (%) | 95% CI |
|---|---|---|---|---|
| Adoption of IHC | ||||
| Yes | 10/82 (12.2) | 6.0–21.3 | 4/67 (6.0) | 1.7–14.6 |
| No | 11/82 (13.4) | 6.9–22.7 | 4/67 (6.0) | 1.7–14.6 |
| No. TANa identified | ||||
| 1 | 2/10 (20.0) | 2.5–55.6 | 1/9 (11.1) | 0.3–48.2 |
| 2 | 1/18 (5.6) | 0.1–27.3 | 0/13 (0) | 0.0–24.7 |
| >2 | 7/54 (13.0) | 5.4–24.9 | 3/45 (6.7) | 1.4–18.3 |
| Time period | ||||
| 2014–2016 | 7/45 (15.6) | 6.5–29.5 | 4/35 (11.4) | 3.2–26.7 |
| 2017–2021 | 3/37 (8.1) | 1.7–21.9 | 0/32 (0) | 0.0–10.9 |
| Clinical T stage | ||||
| T1–T2 | 7/60 (11.7) | 4.8–22.6 | 4/53 (7.5) | 2.1–18.2 |
| T3–T4 | 3/22 (13.6) | 2.9–34.9 | 0/14 (0) | 0.0–23.2 |
| SLN mapping agent used | ||||
| Single | 7/57 (12.3) | 5.1–23.7 | 3/48 (6.3) | 1.3–17.2 |
| Dual | 3/25 (12.0) | 2.5–31.2 | 1/19 (5.3) | 0.1–26.0 |
| Detection of clipped node | ||||
| Mammography | 5/42 (11.9) | 4.0–25.6 | 3/33 (9.1) | 1.9–24.3 |
| Ultrasound | 2/34 (5.9) | 0.7–19.7 | 0/30 (0) | 0.0–11.6 |
| Not detected | 3/6 (50.0) | 11.8–88.2 | 1/4 (25.0) | 0.6–80.6 |
a
including clipped lymph nodes or sentinel lymph nodes.
ALND, axillary lymph node dissection; IHC, immunohistochemistry; SLN, sentinel lymph node; TAD, targeted axillary dissection; TAN, targeted axillary node.